In summary, our study provides effect size estimates for the recently discovered ABI3 and PLCG2 variants [1] in five different neurodegenerative diseases and an African-American AD case-control cohort and also characterizes the expression patterns of these genes in two brain regions in AD, PSP and controls. The gene discussed is ABI3; the disease is Alzheimer disease.